Transvaginal ultrasound (TVU) cervical length
(CL) screening for prediction and prevention of spontaneous preterm birth (SPTB) is among the most transformative clinical changes in obstetrics in the last decades.
Argyelan noted that the current Society for Maternal-Fetal Medicine (SMFM) position regarding cervical length
screening is that it should not yet be universally mandated for singleton pregnancies without a prior history of preterm birth.
Secondary outcomes of interest included cervical length
at 2 weeks after the start of treatment, neonatal outcomes, complications, and route of delivery.
Combined fetal fibronectin and cervical length
and spontaneous preterm birth in asymptomatic triplet pregnancies.
We analyzed five variables: sex, previous fibroscopy, cervical length
(<5 cm, 5.
Such studies (39-41) led to the more recent ACOG Practice Bulletin in 2012 recognizing the utility of routine second trimester cervical length
evaluation even in low risk populations.
Transvaginal cervical length
measurement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis.
Relation of cervical length
at 22-24 weeks of gestation to demographic characteristics and obstetric history.
According to Columbia Laboratories Inc, Prochieve has been filed by Watson with New Drug Application (NDA 22-139) for the prevention of preterm birth in women with a short cervical length
Material and Method: Patients with singleton pregnancy having a history of one or more second trimester losses were selected on the basis of history, physical examination and ultrasound assessment of cervical length
with a cut off of 2.
The risk factors for cervical incompetence include recurrent mid trimester losses, previous pre-term pre-mature rupture of membranes before 32 weeks, cervical length
of less than 25mm prior to 27 weeks and prior cervical trauma (e.
23 January 2012 - Columbia Laboratories Inc (NASDAQ:CBRX) and Watson Pharmaceuticals Inc (NYSE:WPI) said on Friday that the US Food and Drug Administration's (FDA) Advisory Committee for Reproductive Health Drugs came up with a negative opinion on the approval of progesterone vaginal gel 8% for the reduction of risk of preterm birth in women with short uterine cervical length
at the mid-trimester of pregnancy.